Comprehensive computational assessment of ADME properties using mapping techniques

Current Drug Discovery Technologies

Volumn 2, Issue 2, 2005, Pages 99-113

  Balakin, Konstantin V ^a   Ivanenkov, Yan A ^a   Savchuk, Nikolay P ^a   Ivashchenko, Andrey A ^a   Ekins, Sean ^b  

^a CHEMDIV INC   (United States)

^b GeneGo bioinformatics software Inc   (United States)

Author keywords

Absorption; ADME; Cytochrome P450; P glycoprotein; Plasma half life; Sammon non linear maps; Self organizing maps; Support vector machines; Volume of distribution

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLYCOPROTEIN P; PLASMA PROTEIN;

ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; COMPUTER PROGRAM; DIFFUSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; INTESTINE ABSORPTION; NONLINEAR SYSTEM; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

BLOOD PROTEINS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 21744450105     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570163054064666     Document Type: Article

References (85)

1. Welch W., Ruppert J., Jain A.N.: Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. Chem. Biol. 3(6), 449, (1996).
2. Stahl M., Todorov N.P., James T., Mauser H., Boehm H.-J., Dean P.M.: A validation study on the practical use of automated de novo design. J. Comput. Aided Mol. Des. 16(7), 459, (2002).
3. Schneider G., Bohm H.-J.: Virtual screening and fast automated docking methods. Drug Discov. Today 7(1), 64, (2002).
4. Ishchenko A.V., Shakhnovich E.I.: SMall Molecule Growth 2001 (SMoG2001): An improved knowledge-based scoring function for protein-ligand interactions. J. Med. Chem. 45(13), 2770, (2002).
5. Shimada J., Ekins S., Elkin C., Shaknovich E.I., Wery J.-P.: Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs. Targets 1, 196, (2002).
6. Lipinski C.A.: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharm. Toxicol. Methods 44(1), 235, (2000).
7. Walters W.P., Murcko M.A.: Prediction of 'drug-likeness'. Adv. Drug Del. Rev. 54(3), 255, (2002).
8. Oprea T.I.: Current trends in lead discovery: are we looking for the appropriate properties? J. Comput. Aided Mol. Des. 16(5-6), 325, (2002).
9. Wenlock M.C., Austin R.P., Barton P., Davis A.M., Leeson P.D.: A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46(7), 1250, (2003).
10. Ekins S., Boulanger B., Swaan P.W., Hupcey M.A.Z.: Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. 16(5-6), 381, (2002).
11. Ekins S., Rose, J.P.: In silico ADME/Tox: the state of the art. J. Mol. Graph. 20(4), 305, (2002).
12. Van de Waterbeemd H., Gifford E.: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2(3), 192, (2003).
13. Lipinski C.A., Lombarde F., Dominy B.W., Feeney P.J.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 46(1-3), 3, (1997).
14. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D.: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45(12), 2615, (2002).
15. Balakin K.V., Ekins S., Bugrim A., Ivanenkov Y.A., Korolev D., Nikolsky Y.V., Skorenko A.V., Ivashchenko A.A., et al. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab. Dispos. 32(10), 1183, (2004).
16. Norinder U., Haeberlein M.: Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Del. Rev. 54(3), 291, (2002).
17. Thummel K., Shen D.D.: In Goodman & Gilman's the pharmaceutical basis of therapeutics: Tenth K.E.. Ed.; McGraw-Hill: New York, pp. 1924-2023, (2001).
18. Penzotti J.E., Lamb M.L., Evenson E., Grootenhuis P.D.J.: A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem. 45(9), 1737, (2002).
19. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E., Lan L.B., Yasuda K., Shepard R.L., et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61(5), 964, (2002).
20. Guttmann L.: Some necessary conditions for common factor analysis. Psychometrika 19, 149, (1954).
21. Catell R.B.: The scree test for the number of factors. Multi Behav. Res. 1, 245, (1966).
22. Sammon J.W.: A nonlinear mapping for data structure analysis. IEEE Trans. Comp. C-18(5), 401, (1969).
23. Vapnik V.: Statistical learning theory, Wiley: New York, (1998).
24. rd edn, Springer Verlag: New York, (2000).
25. Agrafiotis O.K., Myslik J.C., Salemme F.R.: Advances in diversity profiling and combinatorial series design. Mol. Divers. 4, 1, (1999).
26. Agrafiotis O.K., Lobanov V.S.: Nonlinear mapping networks. J. Chem. Inf. Comp. Sci. 40(3), 1356, (1997).
27. Yoshida F., Topliss J.G.: QSAR model for drug human oral bioavailability. J. Med. Chem. 43(13), 2575, (2000).
28. Clark D.E.: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88(8), 807, (1999).
29. Palm K., Stenberg P., Luthman K., Artursson P.: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14(5), 568, (1997).
30. Wessel M.D., Jurs P.C., Tolan J.W., Muskal S.M.: Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38(4), 726, (1998).
31. Kelder J., Grootenhuis P.D.J., Bayada D.M., Delbressine L.P.C., Ploeman J.-P.: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16(10), 1514, (1999).
32. Luco J.M.: Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J. Chem. Inf. Comput. Sci. 39(2), 396, (1999).
33. Lombardo F., Blake J.F., Curatolo W.J.: Computation of brain-blood partitioning of organic solutes via free energy calculations. J. Med. Chem. 39(24), 4750, (1996).
34. Crivori P., Cruciani G., Carrupt P.A., Testa B.: Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43(11), 2204, (2000).
35. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., Hamman M.A., Hall S.D., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30(8), 883, (2002).
36. Nelson D.R.: Introductory remarks on human CYPs. Drug Metab. Rev. 34(1-2), 1, (2002).
37. Ekins S.: Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 9(10), 276, (2004).
38. VandenBranden M., Wrighton S.A., Ekins S., Gillespie J.S., Binkley S.N., Binkley S.N., Ring B.J., Gadberry M.G., et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab. Dispos. 26(11), 1063, (1998).
39. Ekins S., Maenpaa J., Wrighton S.A.: In Handbook of drug metabolism; Marcel Dekker: New York, pp. 363-399, (1999).
40. Mansch C.: The QSAR paradigm in the design of less toxic molecules. Drug Metab. Rev. 15(7), 1279, (1984).
41. Mansch C., Zhang L.: Quantitative structure-activity relationships ofcytochrome P-450 Drug Metab. Rev. 25(1-2), 1, (1993).
42. Austel V.A.: Quantitative structure-activity relationships of drugs, Academic Press, pp. 437, (1983).
43. Lewis D.F.V.: On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. Biochem. Pharmacol. 60(3), 293, (2000).
44. de Groot MJ., Ekins S.: Pharmacophore modeling of cytochromes P450. Adv. Drug Del. Rev. 54(3), 367, (2002).
45. Ekins S., de Groot M., Jones J.P.: Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 29(7), 936, (2001).
46. Jones J.P., He M., Trager W.F., Rettie A.E.: Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metabol. Dispos. 24(1), 1, (1996).
47. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B.: The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32(3-4), 339, (2000).
48. Ekins S., Stresser D.M., Williams J.A.: In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24(4), 191, (2003).
49. Korolev D., Balakin K.V., Nikolsky Y., Kirillov E., Ivanenkov Y.A., Savchuk N.P., Ivashchenko A.A., Nikolskaya T.: Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. 46(17), 3631, (2003).
50. Bugrim A., Nikolskaya T., Nikolsky Y.: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today 9(3), 127, (2004).
51. Balakin K.V., Ekins S., Bugrim A., Ivanenkov Y.A., Korolev D., Nikolsky Y.V., Ivashchenko A.A., Savchuk N.P., et al. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab. Dispos. 32(10), 1111, (2004).
52. Shen M., Xiao Y., Golbraikh A., Gombar V.K., Tropsha A.: Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. 46(14), 3013, (2003).
53. Colmenarejo G., Alvarez-Pedraglio A., Lavandera J.-L.: Cheminformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 44(25), 4370, (2001).
54. Saiakhov R., Stefan L.R., Klopman G.: Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Persp. Drug Disc. Design 19, 133, (2000).
55. van de Waterbeemd H., Smith D.A., Jones B.C.: Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aid. Mol. Des. 15(3), 273, (2001).
56. Kratochwil N.A., Huber W., Müller F., Kansy M., Gerber D.: Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 64(9), 1355, (2002).
57. Andrews C.W., Bennett L., Yu L.X.: Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17(6), 639, (2000).
58. Zhang E.Y., Phelps M.A., Cheng C., Ekins S., Swaan P.W.: Adv. Drug Del. Rev. 54, 354, (2002).
59. Slouch T.R., Gudmundsson O.: Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Del. Rev. 54(3), 315, (2002).
60. Garrigues A., Loiseau N., Delaforge M., Ferte J., Garrigos M., Andre F., Orlowski S.: Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharmacol. 62(6), 1288, (2002).
61. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., Schuetz E., Wikel J.H., Wrighton S.A.: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61(5), 974, (2002).
62. Pajeva I.K., Wiese M.: Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem. 45(26), 5671, (2002).
63. Langer T., Eder M., Hoffmann R.D., Chiba P., Ecker G. F.: Lead identification for modulators of multidrug resistance based on in silica screening with a pharmacophoric feature model. Arch. Pharm. (Weinheim) 337(6), 317, (2004).
64. Pajeva I.K., Globisch C., Wiese M.: Structure-function relationships of multidrug resistance P-glycoprotein. J. Med. Chem. 47(10), 2523, (2004).
65. Lombarde F., Obach R.S., Shalaeva M.Y., Gao F.: Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 45(13), 2867, (2002).
66. Clark R.D., Patterson D.E., Soltanshahi F., Blake J.F., Matthew J.B.: Visualizing substructural fingerprints. J. Mol. Graph. Model 18(4-5), 404, (2000).
67. Ekins S., de Groot M., Jones J.P.: Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 29(7), 936, (2001).
68. Ekins S., Mirny L., Schuetz E.G.: A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm. Res. 19(12), 1788, (2002).
69. Ekins S., Erickson J.A.: A pharmacophore for human pregnane X receptor ligands. Drug Metab. Dispos. 30(1), 96, (2002).
70. Cavalli A., Poluzzi E., De Ponti F., Recanatini M.: Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 45(18), 3844, (2002).
71. Aronov A.M., Goldman B.B.: A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem. 12(9), 2307, (2004).
72. Chen X., Rusinko III A., Young S.S.: Recursive partitioning analysis of a large structure-activity data set using three-dimensional descriptors. J. Chem. Inf. Comput. Sci. 38(6), 1054, (1998).
73. Chen X., Rusinko I.A., Tropsha A., Young S.S.: Automated pharmacophore identification for large chemical data sets. J. Chem. Inf. Comput. Sci. 39(5), 887, (1999).
74. Ekins S., Berbaum J., Harrison R.K.: Generation and validation of rapid computational filters for Cyp2D6 and Cyp3A4. Drug Metab. Dispos. 31(9), 1077, (2003).
75. Young S.S., Gombar V.K., Emptage M.R., Cariello N.F., Lambert C.: Mixture deconvolution and analysis of Ames mutagenicity data. Chemo. Intell. Lab. Sys. 60(), 5, (2002).
76. Marchand-Geneste N., Watson K.A., Alsberg B.K., King R.D.: New approach to pharmacophore mapping and QSAR analysis using inductive logic programming. Application to thermolysin inhibitors and glycogen phosphorylase B inhibitors. J. Med. Chem. 45(2), 399, (2002).
77. Nicolotti O., Gillet V.J., Fleming P.J. Green D.V.S.: Multiobjective optimization in quantitative structure-activity relationships: deriving accurate and interpretable QSARs. J. Med. Chem. 45(23), 5069, (2002).
78. Furey T.S., Christianini N., Duffy N., Bednarski D.W., Schummer M., Haussler D.: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16(10), 906, (2000).
79. Brown M.P.S., Grundy W.N., Lin D., Christianini N., Sugnet C.W., Ares M., Haussler D. Jr.: Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc. Natl. Acad. Sci. USA 97, 262, (2000).
80. Zernov V.V., Balakin K.V., Ivashchenko A.A., Savchuk N.P., Pletnev I.V.: Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J. Chem. Inf. Comp. Sci. 43(6), 2048, (2003).
81. Wold S., Johansson E., Cocchi M.: In 3D-QSAR in drug design; Theory, methods and applications, ESCOM: Leiden, pp. 523-550, (1993).
82. Afzelius L., Masimirembwa C.M., Karlen A., Andersson T.B., Zamora I.: Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. J. Comput. Aided Mol. Des. 16(7), 443, (2002).
83. Rosipal R., Trejo L.J.: Kernel partial least squares regression in reproducing kernel hilbert space. J. Machine Learning Research. 2(12), 97, (2001).
84. Bennett K.P., Embrechts M.J.: In Advances in learning theory; methods, models and applications, IOS Press: Amsterdam, pp. 227-250, (2003).
85. Lundquist S., Renftel M., Brillault J., Fenart L., Cecchelli R., Dehouck M.P.: Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19(7), 976, (2002).